Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, (doi: 10.1002/ehf2.14742) (Early Online Publication)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (Early Online Publication)

Ray, R. et al. (2023) The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.10.006) (PMID:37926238) (Early Online Publication)

Graham, F. J., Friday, J. , Pellicori, P. , Greenlaw, N. and Cleland, J. G.F. (2023) Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease. Heart, 109(17), pp. 1294-1301. (doi: 10.1136/heartjnl-2022-322145) (PMID:37130747)

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)